Nippon Shinyaku Co Ltd banner
N

Nippon Shinyaku Co Ltd
TSE:4516

Watchlist Manager
Nippon Shinyaku Co Ltd
TSE:4516
Watchlist
Price: 4 889 JPY 1.1% Market Closed
Market Cap: ¥343.5B

P/B

1.2
Current
5%
Cheaper
vs 3-y average of 1.2

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
1.2
=
Market Cap
¥338B
/
Total Equity
¥283.9B

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
1.2
=
Market Cap
¥338B
/
Total Equity
¥283.9B

Valuation Scenarios

Nippon Shinyaku Co Ltd is trading below its 3-year average

If P/B returns to its 3-Year Average (1.2), the stock would be worth ¥5 158.03 (6% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+73%
Average Upside
34%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 1.2 ¥4 889
0%
3-Year Average 1.2 ¥5 158.03
+6%
5-Year Average 2 ¥8 454.11
+73%
Industry Average 1.6 ¥6 689.11
+37%
Country Average 1.4 ¥5 952.04
+22%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close
Market Cap P/B P/E
JP
Nippon Shinyaku Co Ltd
TSE:4516
329.5B JPY 1.2 11
US
Eli Lilly and Co
NYSE:LLY
820.3B USD 31.1 40
US
Johnson & Johnson
NYSE:JNJ
548.5B USD 6.7 26.1
CH
Roche Holding AG
SIX:ROG
248.4B CHF 7.7 20.1
UK
AstraZeneca PLC
LSE:AZN
215.6B GBP 5.9 27.9
CH
Novartis AG
SIX:NOVN
218.9B CHF 5.9 19.6
US
Merck & Co Inc
NYSE:MRK
272.8B USD 5.2 14.9
IE
Endo International PLC
LSE:0Y5F
244.4B USD -58.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 6.1 11.5
US
Pfizer Inc
NYSE:PFE
152.3B USD 1.7 19.4
US
Bristol-Myers Squibb Co
NYSE:BMY
116.3B USD 6.3 16.6
P/E Multiple
Earnings Growth PEG
JP
N
Nippon Shinyaku Co Ltd
TSE:4516
Average P/E: 20.7
11
-12%
N/A
US
Eli Lilly and Co
NYSE:LLY
40
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.1
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.9
25%
1.1
CH
Novartis AG
SIX:NOVN
19.6
14%
1.4
US
Merck & Co Inc
NYSE:MRK
14.9
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.4
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.6
16%
1

Market Distribution

In line with most companies in Japan
Percentile
35th
Based on 5 195 companies
35th percentile
1.2
Low
0 — 1.1
Typical Range
1.1 — 2.1
High
2.1 —
Distribution Statistics
Japan
Min 0
30th Percentile 1.1
Median 1.4
70th Percentile 2.1
Max 31 732 017.6

Nippon Shinyaku Co Ltd
Glance View

Market Cap
343.5B JPY
Industry
Pharmaceuticals

Nippon Shinyaku Co., Ltd. stands as a beacon in the Japanese pharmaceutical landscape, weaving a story that begins over a century ago. Originally founded to address the medical needs of its society, the company has strategically evolved its focus, channeling its expertise into two main business domains: pharmaceuticals and functional food. As it carved its niche, Nippon Shinyaku harnessed the power of innovation and research to develop drugs that address critical medical needs, especially in oncology, hematology, and rare diseases. This specialization not only strengthens its foothold but also embodies a moral commitment to enhancing patient quality of life, proving profitable as these fields often present less competition but promise high demand and returns. Alongside its pharmaceutical ventures, Nippon Shinyaku has leveraged the burgeoning wellness trend through its functional food segment, offering products that promote health and prevent disease. This dual approach leverages the company's bioscience expertise and diversifies its revenue streams, shielding it from the volatility often seen in the pharmaceutical sector. By making strategic alliances and collaborations, both domestically and overseas, Nippon Shinyaku accelerates its market penetration and expands its international footprint. As it capitalizes on its robust R&D capabilities, the company anchors its success on a fusion of scientific advancement and strategic acumen, crafting a narrative of resilience and adaptability in a rapidly evolving industry.

Intrinsic Value
4 976.33 JPY
Undervaluation 2%
Intrinsic Value
Price ¥4 889
N
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett